These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22248721)

  • 1. Platinum-based compounds for the treatment of metastatic breast cancer.
    Shamseddine AI; Farhat FS
    Chemotherapy; 2011; 57(6):468-87. PubMed ID: 22248721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-based chemotherapy in metastatic breast cancer: current status.
    Decatris MP; Sundar S; O'Byrne KJ
    Cancer Treat Rev; 2004 Feb; 30(1):53-81. PubMed ID: 14766126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
    Rivera E
    Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Renaissance of platinum-based chemotherapy for metastatic breast cancer.
    Meriggi F; Di Biasi B; Zaniboni A
    J Chemother; 2008 Oct; 20(5):551-60. PubMed ID: 19028616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixabepilone: clinical role in metastatic breast cancer.
    Denduluri N; Swain S
    Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of vinorelbine in the treatment of breast cancer.
    Domenech GH; Vogel CL
    Clin Breast Cancer; 2001 Jul; 2(2):113-28. PubMed ID: 11899783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of anthracycline-resistant metastatic breast carcinoma].
    Kreienberg R
    Praxis (Bern 1994); 1998 Apr; 87(17):573-7. PubMed ID: 9623323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
    Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
    Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer.
    Farhat FS; Temraz S; Kattan J; Ibrahim K; Bitar N; Haddad N; Jalloul R; Hatoum HA; Nsouli G; Shamseddine AI
    Clin Breast Cancer; 2011 Dec; 11(6):384-9. PubMed ID: 21993011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
    Tkaczuk KH
    Clin Ther; 2009; 31 Pt 2():2273-89. PubMed ID: 20110041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer.
    Awada A
    Forum (Genova); 2002; 12(1):4-15. PubMed ID: 12634907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current trends in pharmacotherapy of breast cancer].
    Boér K
    Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment.
    Ott I; Gust R
    Anticancer Agents Med Chem; 2007 Jan; 7(1):95-110. PubMed ID: 17266507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of endocrine resistant breast cancer.
    Sundar S; Decatris MP; O'Byrne KJ
    J Br Menopause Soc; 2004 Mar; 10(1):16-23. PubMed ID: 15107207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current State of Platinum Complexes for the Treatment of Advanced and Drug-Resistant Breast Cancers.
    Biersack B; Schobert R
    Adv Exp Med Biol; 2019; 1152():253-270. PubMed ID: 31456188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.